search
Back to results

CareConekta: A Smartphone App to Improve Engagement in HIV Care

Primary Purpose

HIV/AIDS, Pregnancy Related

Status
Completed
Phase
Not Applicable
Locations
South Africa
Study Type
Interventional
Intervention
CareConekta
Sponsored by
Vanderbilt University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for HIV/AIDS

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. We will only enroll participants attending the Gugulethu Community Health Centre, near Cape Town, South Africa
  2. HIV-positive
  3. adult (≥18 years)
  4. pregnant (≥28 weeks)
  5. own a smartphone that meets the technical requirements
  6. willing to opt-in to installation of CareConekta on her personal phone and to mobility tracking
  7. demonstrate the ability to read simple text language
  8. willing to be randomized

Exclusion Criteria:

  • If an interested participant meets all of the inclusion criteria, there are no additional exclusion criteria

Sites / Locations

  • Gugulethu Community Health Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control

Intervention

Arm Description

The control arm will receive standard CareConekta, which will track their mobility with no additional features.

The intervention arm will receive standard CareConekta, plus text notifications of nearby ART facilities when they have traveled >50 km from the study site for >7 days. At enrollment, participants in the intervention arm also will be able to opt-in to phone call(s) and/or WhatsApp message(s) from study staff to when they have met this travel threshold. The study staff calls and messages will ask about medication supply and will provide assistance with nearby facilities, if requested.

Outcomes

Primary Outcome Measures

Mobility Prevalence
The investigators will report the number of participants who travel during the study period (defined as 3 or more nights away from home), over the denominator of all participants who completed follow-up.
Median Number of Trips Per Person
Among those who travel, the investigators will report the median and interquartile range number of trips during the study period.
CareConekta Feasibility: Same Phone at Follow-up
The number of participants who report using the same phone from enrollment at follow-up

Secondary Outcome Measures

Timing of Travel
The investigators will determine timing of travel as it relates to delivery date, which will be obtained from participant questionnaire.
Permanent Move
Was the move permanent (yes/no)
CareConekta Feasibility: GPS Disabled During the Study Period
The number of participants who disabled GPS during the study period
CareConekta Feasibility -- Participant Reported Sharing Phone
The number of participants who reported sharing their phone with another person during the study period
CareConekta Feasibility -- Participant Ever Opened App
The number of participants who reported opening the CareConekta app at least once after enrollment visit
CareConekta Feasibility -- Participant Used the App to Locate New Health Facilities
The number of participants who reported using the CareConekta app to locate a new health facility.
CareConekta Initial Efficacy -- Maternal Engagement in HIV Care
The investigators will assess the initial efficacy of CareConekta as an intervention to improve engagement in HIV care. Efficacy will be assessed as the association (estimating adjusted hazard ratios) between study arm and maternal retention in care and viral suppression 6 months after delivery.
CareConekta Initial Efficacy -- Infant Outcomes
The investigators will assess the initial efficacy of CareConekta as an intervention to improve engagement in HIV care. Efficacy will be assessed as the association (estimating adjusted hazard ratios) between study arm and vertical HIV transmission and completion of 10-week infant HIV PCR test.
Impact of Mobility -- Maternal Engagement in HIV Care
In the standard arm, the investigators will assess the association (estimating hazard ratios) between mobility during the study period and engagement in HIV care for the mother (defined as retention in care and viral suppression six months after delivery).
Impact of Mobility -- Infant Outcomes
In the standard arm, the investigators will assess the association (estimating hazard ratios) between mobility during the study period and completion of routine early infant diagnosis.

Full Information

First Posted
January 22, 2019
Last Updated
January 5, 2023
Sponsor
Vanderbilt University
Collaborators
University of Cape Town, University of California, San Francisco, National Institute of Mental Health (NIMH)
search

1. Study Identification

Unique Protocol Identification Number
NCT03836625
Brief Title
CareConekta: A Smartphone App to Improve Engagement in HIV Care
Official Title
CareConekta: A Pilot Study of a Smartphone App to Improve Engagement in Postpartum HIV Care in South Africa
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Completed
Study Start Date
December 9, 2019 (Actual)
Primary Completion Date
November 30, 2021 (Actual)
Study Completion Date
November 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University
Collaborators
University of Cape Town, University of California, San Francisco, National Institute of Mental Health (NIMH)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Population mobility is common in South Africa, but important research gaps exist describing this mobility and its impact on engagement in HIV care, particularly among pregnant and postpartum women. Through this study, the investigators propose to test a smartphone application - CareConekta - to conduct essential formative work on mobility and evaluate this app as an intervention to facilitate engagement in HIV care during times of mobility. This work is critical to adapting CareConekta for widespread use, providing critical information about mobility during the peripartum period and the impact on engagement in HIV care, and piloting this intervention to improve engagement.
Detailed Description
South Africa is home to the world's largest antiretroviral therapy (ART) program, but sustaining high retention along the HIV care continuum has proven challenging in the country and throughout the wider region. Population mobility is common in South Africa, but important research gaps exist describing this mobility and its impact on engagement in HIV care. Postpartum women and their infants in South Africa are known to be at high risk of dropping out of HIV care after delivery and are frequently mobile. The investigators recently developed a beta version of a smartphone application (app) - CareConekta - that detects a user's smartphone location to allow for prospective characterization of mobility. Through this three-year study, the investigators propose to test CareConekta to conduct essential formative work on mobility and evaluate an intervention - the CareConekta app plus text notifications and optional staff phone calls and/or WhatsApp messages - to facilitate engagement in HIV care during times of mobility. After first adapting CareConekta to use appropriate smartphone technology for the local population, the investigators will characterize mobility among South African women during the peripartum period and its impact on engagement in HIV care. The investigators also will evaluate the acceptability, feasibility, and initial efficacy of using CareConekta as an intervention to improve engagement in HIV care. The investigators will work with a South African technology company with a strong connection to the South African Department of Health to adapt the app prior to enrolling study participants. The study will observe mobility within an observational cohort and will then assess the impact of the intervention among participants who travel during the study period. This work is critical to adapting an existing app for widespread use, providing critical information about mobility during the peripartum period and the impact on engagement in HIV care, and piloting an intervention to improve engagement. This study will lay the necessary groundwork for a larger efficacy trial of the intervention within different geographic settings.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV/AIDS, Pregnancy Related

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
No Intervention
Arm Description
The control arm will receive standard CareConekta, which will track their mobility with no additional features.
Arm Title
Intervention
Arm Type
Experimental
Arm Description
The intervention arm will receive standard CareConekta, plus text notifications of nearby ART facilities when they have traveled >50 km from the study site for >7 days. At enrollment, participants in the intervention arm also will be able to opt-in to phone call(s) and/or WhatsApp message(s) from study staff to when they have met this travel threshold. The study staff calls and messages will ask about medication supply and will provide assistance with nearby facilities, if requested.
Intervention Type
Other
Intervention Name(s)
CareConekta
Intervention Description
CareConekta is a smartphone app that uses the phone's GPS to prospectively characterize mobility and allow for intervening in real-time. CareConekta uses the phone's built-in GPS system to record location coordinates.
Primary Outcome Measure Information:
Title
Mobility Prevalence
Description
The investigators will report the number of participants who travel during the study period (defined as 3 or more nights away from home), over the denominator of all participants who completed follow-up.
Time Frame
Baseline to End of Study (up to 2 years)
Title
Median Number of Trips Per Person
Description
Among those who travel, the investigators will report the median and interquartile range number of trips during the study period.
Time Frame
Baseline to End of Study (up to 2 years)
Title
CareConekta Feasibility: Same Phone at Follow-up
Description
The number of participants who report using the same phone from enrollment at follow-up
Time Frame
Baseline to End of Study (up to 2 years)
Secondary Outcome Measure Information:
Title
Timing of Travel
Description
The investigators will determine timing of travel as it relates to delivery date, which will be obtained from participant questionnaire.
Time Frame
Baseline to End of Study (up to 2 years)
Title
Permanent Move
Description
Was the move permanent (yes/no)
Time Frame
Baseline to End of Study (up to 2 years)
Title
CareConekta Feasibility: GPS Disabled During the Study Period
Description
The number of participants who disabled GPS during the study period
Time Frame
Baseline to End of Study (up to 2 years)
Title
CareConekta Feasibility -- Participant Reported Sharing Phone
Description
The number of participants who reported sharing their phone with another person during the study period
Time Frame
Baseline to End of Study (up to 2 years)
Title
CareConekta Feasibility -- Participant Ever Opened App
Description
The number of participants who reported opening the CareConekta app at least once after enrollment visit
Time Frame
Baseline to End of Study (up to 2 years)
Title
CareConekta Feasibility -- Participant Used the App to Locate New Health Facilities
Description
The number of participants who reported using the CareConekta app to locate a new health facility.
Time Frame
Baseline to End of Study (up to 2 years)
Title
CareConekta Initial Efficacy -- Maternal Engagement in HIV Care
Description
The investigators will assess the initial efficacy of CareConekta as an intervention to improve engagement in HIV care. Efficacy will be assessed as the association (estimating adjusted hazard ratios) between study arm and maternal retention in care and viral suppression 6 months after delivery.
Time Frame
6 months after delivery
Title
CareConekta Initial Efficacy -- Infant Outcomes
Description
The investigators will assess the initial efficacy of CareConekta as an intervention to improve engagement in HIV care. Efficacy will be assessed as the association (estimating adjusted hazard ratios) between study arm and vertical HIV transmission and completion of 10-week infant HIV PCR test.
Time Frame
10 weeks after delivery, study end
Title
Impact of Mobility -- Maternal Engagement in HIV Care
Description
In the standard arm, the investigators will assess the association (estimating hazard ratios) between mobility during the study period and engagement in HIV care for the mother (defined as retention in care and viral suppression six months after delivery).
Time Frame
6 months after delivery
Title
Impact of Mobility -- Infant Outcomes
Description
In the standard arm, the investigators will assess the association (estimating hazard ratios) between mobility during the study period and completion of routine early infant diagnosis.
Time Frame
10 weeks after delivery, study end

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
We will enroll only pregnant women.
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: We will only enroll participants attending the Gugulethu Community Health Centre, near Cape Town, South Africa HIV-positive adult (≥18 years) pregnant (≥28 weeks) own a smartphone that meets the technical requirements willing to opt-in to installation of CareConekta on her personal phone and to mobility tracking demonstrate the ability to read simple text language willing to be randomized Exclusion Criteria: If an interested participant meets all of the inclusion criteria, there are no additional exclusion criteria
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kate Clouse, PhD, MPH
Organizational Affiliation
Vanderbilt University School of Nursing
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gugulethu Community Health Centre
City
Cape Town
Country
South Africa

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified datasets will be made available by request, subject to agreement to (1) a commitment to use the data only for research purposes and not to identify any individual participant; (2) a commitment to secure the data using appropriate computer technology and established security measures; (3) a plan for the dissemination of results; (4) appropriate authorship and recognition of all partners; and (5) a commitment to destroy or return the data after analyses are completed.
IPD Sharing Time Frame
Anytime, by request
Citations:
PubMed Identifier
32164771
Citation
Clouse K, Phillips TK, Camlin C, Noholoza S, Mogoba P, Naidoo J, Langford R, Weiss M, Seebregts CJ, Myer L. CareConekta: study protocol for a randomized controlled trial of a mobile health intervention to improve engagement in postpartum HIV care in South Africa. Trials. 2020 Mar 12;21(1):258. doi: 10.1186/s13063-020-4190-x.
Results Reference
derived

Learn more about this trial

CareConekta: A Smartphone App to Improve Engagement in HIV Care

We'll reach out to this number within 24 hrs